BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 16272756)

  • 1. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
    Kimura N; Masuda S; Tanihara Y; Ueo H; Okuda M; Katsura T; Inui K
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):379-86. PubMed ID: 16272756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
    Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
    J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.
    König J; Zolk O; Singer K; Hoffmann C; Fromm MF
    Br J Pharmacol; 2011 Jun; 163(3):546-55. PubMed ID: 20883471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
    Zhang G; Ma Y; Xi D; Rao Z; Sun X; Wu X
    Biopharm Drug Dispos; 2019 Jan; 40(1):3-11. PubMed ID: 30488476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1.
    Li L; Song F; Tu M; Wang K; Zhao L; Wu X; Zhou H; Xia Z; Jiang H
    Int J Pharm; 2014 Apr; 465(1-2):5-10. PubMed ID: 24530383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
    Nies AT; Herrmann E; Brom M; Keppler D
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium.
    Deutsch B; Neumeister C; Schwantes U; Fromm MF; König J
    Mol Pharm; 2019 Feb; 16(2):510-517. PubMed ID: 30656943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
    Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
    Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.
    Jonker JW; Wagenaar E; Van Eijl S; Schinkel AH
    Mol Cell Biol; 2003 Nov; 23(21):7902-8. PubMed ID: 14560032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.
    Choi MK; Song IS
    Biopharm Drug Dispos; 2012 Apr; 33(3):170-8. PubMed ID: 22415520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency.
    Schömig E; Lazar A; Gründemann D
    Handb Exp Pharmacol; 2006; (175):151-80. PubMed ID: 16722235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.
    Jung N; Lehmann C; Rubbert A; Schömig E; Fätkenheuer G; Hartmann P; Taubert D
    Infection; 2013 Apr; 41(2):379-85. PubMed ID: 22875535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal organic cation and nucleoside transport.
    Chen R; Jonker JW; Nelson JA
    Biochem Pharmacol; 2002 Jul; 64(2):185-90. PubMed ID: 12123738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
    Wang DS; Jonker JW; Kato Y; Kusuhara H; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2002 Aug; 302(2):510-5. PubMed ID: 12130709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
    Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.